A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia

NCT ID: NCT05146778

Last Updated: 2025-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

230 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-16

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 230 patients undergoing mastectomy, the investigators will compare opioid-free anesthesia (OFA) versus conventional opioid-based anesthesia in terms of chronic pain. The enrolled patients will be randomly assigned into two groups with 1:1 ratio. Chronic pain will be evaluated at 1 year after mastectomy based on the Breast Cancer Pain Questionnaire (BCPQ). Baseline pain sensitivity test and psychologic evaluation will be done before operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study population

1. All of patients will undergo mastectomy with or without immediate breast reconstruction.
2. 230 patients will be enrolled.

Intervention

1. OFA group will be sedated using dexmedetomidine and lidocaine.
2. Conventional opioid anesthesia group will be sedated using remifentanil.

Pain screening

1. Breast Cancer Pain Questionnaire (BCPQ)
2. Pain-detect, HADS, EQ-5D, PHQ-15 (somatic symptom), PCS (pain catastrophizing), BFI (big five inventory), HAM-A\&D, Pressure algometry (Pain sensitivity), Quantitative sensory test (pinprick)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Mastectomy Pain, Chronic Pain, Post Operative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1. Control arm: Conventional Anesthesia with opioid
2. Interventional arm: Opiod-free Anesthesia with dexmedetomidine and lidocaine
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Patients will be not aware of which type of anesthesia would be applied during operation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Opioid-free anesthesia group

OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.

Group Type ACTIVE_COMPARATOR

Opioid-free anesthesia

Intervention Type PROCEDURE

OFA group will be sedated using dexmedetomidine and lidocaine.

Conventional anesthesia group with opioid

Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.

Group Type ACTIVE_COMPARATOR

Conventional opioid-based anesthesia

Intervention Type PROCEDURE

Conventional opioid-based anesthesia group will be sedated using remi-fentanyl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Opioid-free anesthesia

OFA group will be sedated using dexmedetomidine and lidocaine.

Intervention Type PROCEDURE

Conventional opioid-based anesthesia

Conventional opioid-based anesthesia group will be sedated using remi-fentanyl

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dexmedetomidine and lidocaine-based anesthesia Remi-fentanyl

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All of patients will undergo mastectomy with or without immediate breast reconstruction.

Exclusion Criteria

* Previous history of breast surgery
* Allergy to drug
* Other cancer history
* Underlying psychologic disorder
* Patients with chronic pain requiring pain killers
* Baseline SpO2 \<95%
* Left ventricular EF \<40%
* Bradycardia as HR \<50 bpm
* BMI \>35kg/m2
* Pregnant woman
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gangnam Severance Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sung Gwe Ahn

Assocaite Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sung Gwe G Ahn, M.D.,Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Gangnam Severance Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gangnam Severance Hospital

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sung Gwe Ahn, M.D.,Ph.D.

Role: CONTACT

82220194402

Soong June Bae, M.D.

Role: CONTACT

82220193370

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sung Gwe Ahn, MD, PhD

Role: primary

82-2-2019-3370

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-0568-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Speeding Recovery From Pain and Opioid Use
NCT03388814 WITHDRAWN EARLY_PHASE1